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INTRODUCTION
Despite the progress made in recent years in diag-
nostic methods and surgical treatment of esophageal 
cancer, the long term survival rate, even following 
radical resection, remains disappointing. Complete 
macro and microscopic resection of  the primary 
tumor including its lymph nodes is achieved in only 
a minority of patients. In around 2/3 of patients, the 
tumor has already advanced locally and extended 
beyond the wall of  the esophagus by the time it is 
diagnosed, i.e. the tumor has already invaded the 
adventitia (T3) and adjacent structures (T4)(1, 8, 11, 14, 28).
Consequently, multidisciplinary therapeutic strat-
egies using neoadjuvant and/or adjuvant principles 
have increasingly attracted the attention of the scien-
tific community(7, 13, 15, 18, 21, 29).
The main etiologies of squamous cell carcinoma 
(SCC) are smoking and alcohol consumption, con-
sumption of hot food and drinks, preserved vegetables 
(nitrous compounds), infectious agents (human pap-
NEOADJUVANT CHEMORADIOTHERAPY 
AND SURGERY COMPARED WITH SURGERY 
ALONE IN SQUAMOUS CELL CARCINOMA 
OF THE ESOPHAGUS
Nelson Adami ANDREOLLO, Valdir TERCIOTI Jr.,  
Luiz Roberto LOPES and João de Souza COELHO-NETO
ABSTRACT - Context - Despite progress in recent years in methods of diagnosis and surgical treatment of esophageal cancer, there is 
still controversy about the benefits from neoadjuvant chemoradiotherapy. Objective - To analise the survival of patients submitted 
to esophagectomy for squamous cell carcinoma of the esophagus with or without neoadjuvant chemoradiotherapy. Method - A 
retrospective, non-randomized study conducted using the medical charts of patients operated for squamous cell carcinoma of the 
esophagus at the School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil between 1979 
and 2006. The Kaplan-Meier analysis was used to calculate survival curves and the log-rank test to compare data in each group. 
The significance level was settled as 5%. Results - A total of 123 patients were evaluated in this study, divided into three groups: 
I - 26 (21.2%) patients submitted to esophagectomy alone; II - 81 (65.8%) patients submitted to neoadjuvant radiotherapy plus 
esophagectomy and III - 16 (13%) patients submitted to neoadjuvant chemoradiotherapy plus esophagectomy. A statistically sig-
nificant survival was recorded between the groups (log rank = 6.007; P = 0.05), survival being greatest in the group submitted to 
neoadjuvant chemoradiotherapy, followed by the group submitted to neoadjuvant radiotherapy compared to the group submitted 
to esophagectomy alone as the initial treatment of choice. Conclusion - Radiotherapy and chemotherapy neoadjuvants in patients 
with squamous cell carcinoma of the esophagus offers benefits and increases survival.
HEADINGS – Esophageal neoplasms. Carcinoma, squamous cell. Esophagectomy. Chemotherapy, adjuvant. Radiotherapy, adjuvant.
Declared conflict of interest of all authors: none
Department of Surgery, School of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
Financial Support: School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Correspondence: Prof. Nelson Adami Andreollo - Departamento de Cirurgia da Faculdade de Ciências Médicas da UNICAMP - Cidade Universitária s/nº - Barão Geraldo 
- 13083-970 - Campinas, SP, Brazil. E-mail: nandreollo@hotmail.com
illoma virus), socioeconomic factors (malnutrition), 
celiac sprue, Plummer-Vinson syndrome, micronutrient 
deficiencies (riboflavin, vitamins A, C and E, zinc and 
molybdenum), palmar tylosis (a rare autosomal domi-
nant disease), previous radiotherapy, previously treated 
neoplasias of  the head/neck, idiopathic achalasia, 
chagasic megaesophagus and previous caustic steno- 
sis(4, 5, 6, 7, 18, 20). On the other hand, adenocarcinoma in the 
distal third of the esophagus is closely associated with 
intestinal metaplasia of the Barrett’s esophagus and 
therefore related to chronic gastroesophageal reflux(5).
In Brazil for the year 2012, were expected 7,770 
new cases of esophageal cancer in men and 2,650 in 
women. These values correspond to an estimated risk 
of  eight new cases in men and three in women per 
100,000 habitants and rendering this form of cancer 
the 8th most common type in the Brazilian popula-
tion. Moreover, the incidence is higher in the south 
and southeast of the country(4, 6).
The objective of this non-randomized, retrospec-
tive study was to evaluate the differences in survival of 
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patients operated for SCC of the esophagus with or without 
the addition of neoadjuvant therapy.
METHOD
The protocol of this study was approved by the Ethics 
Committee of  the Internal Review Board of  the School 
of Medical Sciences at the University of Campinas (UNI-
CAMP) and included patients operated for squamous cell 
carcinoma of the esophagus between 1979 and 2006.
The criteria for inclusion were: 1) patients adults without 
age limit and with esophageal cancer submitted to surgical 
resection; 2) histological diagnosis of squamous cell carcino-
ma; and 3) neoadjuvant radiotherapy and/or chemotherapy. 
Patients whose charts could not be located and those with 
incomplete data were excluded from the study.
A total of 123 patients divided in groups were included in 
the study: I - 26 (21%) patients submitted to esophagectomy 
alone (ages = 22 males and 4 females; ethnicities: 21 whites 
and 5 blacks); II – 81 (65.8%) patients submitted to neoad-
juvant radiotherapy (ages: 71 males and 10 females; ethnic-
ities: 64 whites and 17 blacks); and III - 16 (13%) patients 
submitted to neoadjuvant radiotherapy and chemotherapy 
(ages: 14 males and 2 females; ethnicities: 15 whites and 1 
black). The mean age (SD = standard deviation) of the three 
groups were respectively: 53.8 years (SD = 11.7), 53.7 years 
(SD = 8.2) and 57.4 years (SD = 8.8).
Pathological staging was performed according to the 6th 
edition of the UICC-AJCC TNM classification for esoph-
ageal cancer(23).
The Fisher’s exact test was used to calculate differences 
of the groups, staging and postoperative complications. The 
chi-square test (χ2) was used to calculate the differences of 
the site of tumors, tumor recurrence and complications. The 
Kaplan-Meier analysis was used to calculate survival curves 
and the log-rank test to compare data in each group the 
significance level was settled as 5% (P<0.05).
RESULTS
There were no statistically significant differences between 
the three groups with respect to gender, age or ethnicity 
(Fischer’s test P = 0.3507).
The surgical technique performed in the three groups con-
sisted of transmediastinal subtotal esophagectomy followed 
by esophagogastroplasty using an isoperistaltic gastric tube 
placed in the mediastinum, while cervical esophagogastric 
anastomosis was used to reconstruct the digestive passage 
in accordance with the technique described by Pinotti(19) and 
Sugimachi et al.(22).
The mean dose of  radiation therapy in group II was 
3,762.71 cGy (SD = 792.62) and 4,212.5 cGy in group III. 
There were no significant differences between the two groups 
with respect either to the total dose used or the interval be-
tween radiotherapy and surgery.
The neoadjuvant chemotherapy employed the cisplatin 
(one to two cycles of 75 mg/m2 for 4 days (D1-D4) associated 
or not with 5-fluorouracil (1000 mg/m2) administered as a 
continuous infusion on D1.
The most common location of the tumor was: 1) mid-
dle third in 50% of the cases and in the distal third of the 
esophagus in 50% in the groups I and II; 2) middle third of 
the esophagus in 79% of the cases and in the distal third in 
21% in group III. Therefore in the group III the tumor was 
located in the middle third of the esophagus in a significantly 
greater number of cases compared to the other two groups 
(χ2; P = 0.0043, P<0.05).
No statistically significant difference was found between 
the groups with respect to staging (Fisher’s exact test; 
P = 0.2013), postoperative complications (Fisher’s exact 
test; P = 0.0635) or the prevalence of  tumor recurrence 
 (χ2, P = 0.3960) (Table 1).
The distribution of  perioperative complications and 
deaths are shown in Table 2. There were no statistically 
significant differences in complication rates between groups 
TABLE 1. Staging of tumors (6th edition of the UICC-AJCC TNM classification) according to the treatment employed in the three groups studied
Stage          Surgery alone        Neoadjuvant radiotherapy Neoadjuvant radiotherapy + chemotherapy
n % n % n %
0 0 0 13 16.04 5 31.25
I 6 23.07 7 8.64 3 18.75
IIA 11 42.3 34 41.98 4 25 
IIB 3 11.55 16 19.76 2 12.5
III 6 23.08 11 13.58 2 12.5
IV 0 0 0 0 0 0
TABLE 2. Surgical morbidity / mortality compared with the treatments employed in the groups studied
Complications
Surgery alone Neoadjuvant radiotherapy Neoadjuvant radiotherapy + chemotherapy
n % n % n %
Intraoperative hemorrhage 0 0 4 4.93 1 6.25
Chest drainage 14 53.84 64 79 12 75
Bronchopneumonia 3 11.53 18 22.22 4 25
Anastomotic fistula/stenosis 12 46.15 32 39.5 11 6.25
Perioperative deaths 3 11.54 10 12.35 1 6.25
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with the exception of chest drainage, the incidence of which 
was significantly lower in the group of patients submitted 
to surgery alone. Statistical analysis of  the complications 
among three groups described above showed a) intraopera-
tive hemorrhage: P = 0.5072 (Fisher’s exact test); b) fistula/
stenosis: P = 0.0978 (χ2); c) chest drainage: P = 0.0411 (χ2); 
d) bronchopneumonia: P = 0.4414 (Fisher’s exact test) and 
perioperative death: P = 1.000 (Fisher’s exact test).
The survival for the groups, calculated using the Ka-
plan-Meier analysis, is shown in Figure 1 with the exception 
of the patients who died within 30 days of surgery, who were 
excluded from this calculation. Therefore was observed a 
statistically significant difference between the groups (log 
rank = 6.007; P = 0.05), and survival was greater in the group 
submitted to neoadjuvant chemoradiotherapy (group III), 
followed by the group submitted to neoadjuvant radiotherapy 
(group II) compared to the group submitted to esophagec-
tomy alone (group I) as the initial treatment of choice. The 
follow-up and survival time, the number of deaths and sur-
vivals, and the statistically significant differences (standard 
error, 95% confidence interval and P-values) between the 
groups are shown in Table 3.
DISCUSSION
The prognosis of patients with squamous cell carcinoma 
of the esophagus remains poor despite advances made over 
recent years in the diagnosis and treatment of this neoplasia. 
Many authors have discussed and recommended neoadjuvant 
therapy emphasizing the need to implement this therapeutic 
option and the advantages obtained with this treatment. 
The benefits are: 1) improvement in the clinical condition 
of the patient prior to surgery, since tumor size is reduced, 
facilitating food intake, even solid food; 2) reduction in 
tumor size, improving the possibility of complete resection 
and eliminating systemic micrometastases; 3) devitalization 
of tumor cells, thereby minimizing the risk of intraopera-
tive metastasis; 4) administration of more aggressive doses 
of cisplatin combined with other drugs; 5) to improve the 
possibility of complete resection of the lesion, and prolong 
both overall and disease-free survival(13, 15, 18, 21, 24, 27, 28).
In a randomized study carried out in France, Le Prise et 
al.(12) evaluated the benefits of neoadjuvant chemoradiother-
apy (two cycles of 5-fluouracil and cisplatin concomitantly 
with 20 Gy of radiotherapy) compared to a control group 
in which only surgery was performed. These investigators 
concluded that neoadjuvant therapy failed to result in any 
significant difference in intraoperative mortality or in the 
survival time of patients with squamous cell carcinoma of 
the esophagus.
Bosset et al.(3) in a randomized, multicenter study per-
formed in Europe, compared neoadjuvant chemoradiother-
apy followed by surgery (combined therapy) with surgical 
treatment alone in stage I or II SCC of the esophagus. These 
investigators concluded that no improvement occurred in 
overall survival, however, disease-free survival increased.
Urba et al.(25) conducted a randomized study in the United 
States in 100 patients operated for esophageal cancer com-
paring surgery alone (group I) with neoadjuvant chemo-
radiotherapy (group II), and concluded that there was no 
statistically significant difference in survival.
In a randomized, prospective study carried out in Italy, 
Ancona et al.(2) analysed two groups of patients (41 patients 
in each group) with resectable squamous cell carcinoma of 
the esophagus submitted to surgery alone (group A) with 
patients submitted to neoadjuvant chemotherapy (group B), 
TABLE 3. The follow-up and survival time, the number of deaths and survivals and statistic analysis in the three groups studied
Surgery Surgery + radiotherapy Surgery + radiotherapy + chemotherapy
No. of patients 23 71 15
No. of late deaths 12 23 3
Percentage of deaths 52.2 32.4 20.0
Mean time of follow-up (months) 32.43 65.75 87.28
Standard error 7.81 9.43 12.21
95% confidence interval 17.12-47.74 47.26-84.23 63.34–111.22
P-value
Surgery versus surgery + radiotherapy 0.05
Surgery versus surgery + radiotherapy + chemotherapy 0.04
Surgery + radiotherapy versus Surgery + radiotherapy + chemotherapy 0.27
FIGURE 1. Survival curve for the groups of patients submitted to surgery 
alone, radiotherapy + surgery and radiotherapy + chemotherapy + surgery 
(Kaplan-Meier analysis)
Andreollo NA, Tercioti Jr. V, Lopes LR, Coelho-Neto JS.  Neoadjuvant chemoradiotherapy and surgery compared with surgery alone in squamous cell carcinoma of the esophagus
104 Arq Gastroenterol v. 50 no. 2 - abr./jun. 2013 
evaluating overall survival and the impact of  the patient’s 
response to chemotherapy on survival. These investigators 
reported that there was a statistically significant improvement 
in survival only in patients who achieved complete patholog-
ical response to chemotherapy (P = 0.01).
Urschel et al.(26) carried out a meta-analysis of nine ran-
domized, controlled studies involving 1,116 patients with 
SCC of the esophagus in which they compared surgical treat-
ment alone with neoadjuvant chemoradiotherapy followed 
by surgery and reported a 3-year improvement in survival 
and a reduction in locoregional tumor recurrence. The study 
showed a tendency towards an increase in mortality in the 
neoadjuvant chemoradiotherapy group, without statistical 
significance.
Fiorica et al.(9) conducted a meta-analysis of  six con-
trolled, randomized studies and concluded that in patients 
with resectable esophageal cancer, neoadjuvant chemora-
diotherapy followed by radical surgery significantly reduces 
third-year mortality rates compared to surgical treatment 
alone. Nevertheless, these authors concluded that neoadju-
vant chemoradiotherapy resulted in an increase in postop-
erative mortality.
Greer et al.(10) performed a meta-analysis in which six 
randomized studies were evaluated (neoadjuvant chemora-
diotherapy followed by surgery versus surgery alone) and 
concluded that neoadjuvant chemoradiotherapy is associ-
ated with increased overall survival that is not statistically 
significant.
Malthaner et al.(16) conducted a meta-analysis evaluating 
34 randomized studies and 6 meta-analyses involving 13 
different combinations of  neoadjuvant and/or adjuvant 
therapy in resectable esophageal cancer. They concluded that 
surgical treatment alone (i.e. with no neoadjuvant or adjuvant 
therapy) should be recommended as standard treatment for 
cases of resectable thoracic esophageal cancer. The Table 4 
summarizes the mentioned studies.
TABLE 4. Literature review on neoadjuvant therapy in SCC of the esophagus
Author Type of study Number of  patients
Mean survival 
(months) P-value
Le Prise et al.1994(12) Randomized 41 (chemo) vs 45 
(surgery)
11
11
0.56
Bosset et al.1994(3) Randomized 143 (chemo) vs
139 (surgery)
18.6
18.6
0.78
Ancona et al.2001(2) Randomized 47 (chemo) vs
47 (surgery)
25
24
0.01
(only complete pathological response)
Urba et al.2001(25) Randomized 50 (chemo) vs
50 (surgery)
17.6
16.9
0.15
El Nakadi et al.2001(8) Non-randomized 38 (surgery) vs
61 (radio + chemo)
Unavailable
21
0.19
Urschel et al.2002(26) Meta-analysis of nine 
randomized studies
1116 (total)
surgery vs
(radio + chemo)
Odds ratio:
0.79 (1st year)
0.77 (2nd year)
0.66 (3rd year)
0.016 
(3rd year)
Makary et al.2003(14) Non-randomized 76 (surgery) vs
40 (radio + chemo)
17.2 vs
35.7
0.01
Liao et al.2004(13) Non-randomized 72 (surgical) vs
60 (radio + chemo)
12 vs.
62
<0.05
Malaisrie et al.2004(15) Non-randomized 65 (surgical) vs
31 (radio + chemo)
28.7 vs
24.1
0.14
Fiorica et al.2004(9) Meta analysis of six 
randomized studies
390 (surgery) vs
388 (radio + chemo)
Odds ratio:
0.53 (3rd year)
0.03 
(3rd year)
Greer et al.2005(10) Meta-analysis
(6 randomized studies)
364 (surgery) vs
374 (radio + chemo)
Odds ratio:
0.86
0.74
Zhang et al.2005(29) Non-randomized 59 (surgery) vs
56 (radio + chemo)
19.3% (4 years) vs
33.3% (4 years)
<0.05
Morgan et al.2007(18) Non-randomized 117 (chemo) vs
88 (radio + chemo)
24 vs
43
0.03
Andreollo et al.2012 Non-randomized 23 (surgery) vs
71 (radio) vs
16 (radio + chemo)
32.4
65.4
87.2
0.05
Andreollo NA, Tercioti Jr. V, Lopes LR, Coelho-Neto JS.  Neoadjuvant chemoradiotherapy and surgery compared with surgery alone in squamous cell carcinoma of the esophagus
v. 50 no. 2 - abr./jun. 2013  Arq Gastroenterol 105
Van Hagen et al.(27) including patients with resectable 
esophageal tumors treated by surgery alone or weekly ad-
ministration of carboplatin and paclitaxel for 5 weeks and 
concurrent radiotherapy, followed by surgery, demonstrat-
ed that the overall survival was significantly better in the 
chemoradiotherapy-surgery group. They concluded that 
preoperative chemoradiotherapy improved survival among 
patients with potentially curable esophageal or esophago-
gastric-junction cancer.
In the present study, the majority of the patients were at 
stages IIA and IIB(23), although there were cases of stage 0 
in the neoadjuvant therapy groups and stage I in all three 
groups. Postoperative complications and the prevalence of 
tumor recurrence were unrelated to the staging of the disease. 
Statistical analysis showed significant difference in survival 
between the three groups (log rank = 6.007; P = 0.05), sur-
vival being greatest in the group submitted to neoadjuvant 
chemoradiotherapy, followed by the group submitted to 
neoadjuvant radiotherapy in comparison with the group 
submitted to esophagectomy alone. Moreover, neoadjuvant 
therapy did not result in any increase in intra- or postoper-
ative morbidity or mortality rates.
In conclusion, statistically significant differences were 
found in the survival of patients in the groups analysed, con-
firming the benefits of neoadjuvant therapy. It is important to 
emphasize that this is a retrospective nonrandomized study, the 
number of cases submitted to neoadjuvant chemoradiotherapy 
is not as great and therefore the results may have vies despite 
the follow-up period of 5 years and the statistical analyses. 
Nevertheless, further prospective, randomized studies in future 
should be carried out to confirm these new therapeutic strate-
gies for squamous cell carcinoma of the esophagus.
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RESUMO - Contexto - Apesar dos progressos realizados nos últimos anos em métodos de diagnóstico e tratamento cirúrgico do câncer de esôfago, 
ainda há controvérsias sobre os benefícios reais da quimioradioterapia neoadjuvante. Objetivo - Avaliar o tempo de sobrevida em pacientes operados 
de carcinoma de células escamosas do esôfago com ou sem quimioradioterapia neoadjuvante. Método - Estudo retrospectivo, não randomizado, 
realizado com os prontuários dos pacientes submetidos a esofagectomia por carcinoma de células escamosas do esôfago na Faculdade de Ciên-
cias Médicas da Universidade de Campinas (UNICAMP), Campinas, São Paulo, Brasil, entre 1979 e 2006. Na análise estatística, o estimador de 
Kaplan-Meier foi utilizado para calcular as curvas de sobrevivência e do teste log-rank para comparar a sobrevivência em cada grupo. O nível de 
significância foi estabelecido em 5%. Resultados - O total de 123 pacientes foi avaliado neste estudo, dividido em três grupos: I - 26 (21,2%) pacientes 
submetidos a esofagectomia, II - 81 (65,8%) pacientes submetidos a radioterapia neoadjuvante seguido de esofagectomia e III - 16 (13%) submetidos 
a quimioradioterapia neoadjuvante seguido de esofagectomia. Diferença estatisticamente significativa na sobrevida foi registrado entre os grupos 
(log rank = 6,007, P = 0,05), tendo maior sobrevida o grupo submetido a quimioradioterapia neoadjuvante, seguida pelo grupo submetido a radioter-
apia neoadjuvante em comparação com o grupo submetido a esofagectomia apenas como o tratamento inicial de escolha. Conclusão - A radioterapia 
e a quimioterapia neoadjuvantes em pacientes com carcinoma de células escamosas do esôfago oferecem benefícios e aumenta a sobrevida.
DESCRITORES – Neoplasias esofágicas. Carcinoma de células escamosas. Esofagectomia. Quimioterapia adjuvante. Radioterapia adjuvante.
Andreollo NA, Tercioti Jr. V, Lopes LR, Coelho-Neto JS.  Neoadjuvant chemoradiotherapy and surgery compared with surgery alone in squamous cell carcinoma of the esophagus
106 Arq Gastroenterol v. 50 no. 2 - abr./jun. 2013 
REFERENCES
1. Almhanna K, Strosberg JR. Multimodality approach for locally advanced esoph-
ageal cancer. World J Gastroenterol. 2012;18:5679-87.
2. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, 
Bonavina L, Peracchia A. Only pathologic complete response to neoadjuvant che-
motherapy improves significantly the long term survival of patients with resectable 
esopagheal squamous cell carcinoma: final report of a randomized, controlled 
trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-74.
3. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier 
JC, Pavy JJ, Mercier M, Sahmoud T. Chemoradiotherapy followed by surgery 
compared with surgery alone in squamous-cell cancer of the esophagus. N Engl 
J Med. 1997;337:161-7.
4. Brasil. Ministério da Saúde. National Institute of Cancer (INCA): Incidence of 
cancer in Brazil [Internet]. Rio de Janeiro, 2012. Available from: http://www.inca.
gov.br/estimativa/2012/.
5. Conteduca V, Sansonno D, Ingravallo G, Marangi S, Russi S, Lauletta G, Dam-
macco F. Barrett’s esophagus and esophageal cancer: an overview. Int J Oncol. 
2012;41:414-24.
6. de Barros SG, Ghisolfi ES, Luz LP, Barlem GG, Vidal RM, Wolff  FH, Magno 
VA, Breyer HP, Dietz J, Grüber AC, Kruel CD, Prolla JC. High temperature 
“matè” infusion drinking in a population at risk for squamous cell carcinoma of 
the esophagus. Arq Gastroenterol 2000;37:25-30.
7. Denlinger CE, Reed CE. Contemporary management of esophageal malignancy. 
Surg Clin North Am. 2012;92:xvii-xviii.
8. El Nakadi I, Van Laethem JL, Houben JJ, Gay F, Closset J, Van Houtte P, Danhier 
S, Limbosch JM, Lambilliotte JP, Gelin M. Squamous cell carcinoma of the esoph-
agus: multimodal therapy in locally advanced disease. World J Surg. 2002;26:72-8.
9. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, 
Craxì A, Cammà C. Preoperative chemoradiotherapy for oesophageal cancer: a 
systematic review and meta-analysis. Gut. 2004;53:925-30.
10. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradio-
therapy for esophageal carcinoma: a meta-analysis. Surgery. 2005;137:172-7.
11. Hölscher AH, Bollschweiler E. Choosing the best treatment for esophageal 
cancer: criteria for selecting the best multimodal therapy. Recent Results Cancer 
Res. 2012;196:169-77.
12. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Bou-
tin D, Campion JP, Launois B. A randomized study of chemotherapy, radiation 
therapy, and surgery versus surgery for localized squamous cell carcinoma of the 
esophagus. Cancer 1994;73:1779-84.
13. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, 
Vaporciyan AA, Putnam JB Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox 
JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves 
locoregional control in clinical stage II or III esophageal cancer patients. Int J 
Radiat Oncol Biol Phys. 2004;60:1484-93.
14. Makary MA, Kiernan PD, Sheridan MJ, Tonnesen G, Hetrick V, Vaughan B, 
Graling P, Elster E. Multimodality treatment for esophageal cancer: the role of 
surgery and neoadjuvant therapy. Am Surg. 2003;69:693-700.
15. Malaisrie SC, Untch B, Aranha GV, Mohideen N, Hantel A, Pickleman J. Neo-
adjuvant chemoradiotherapy for locally advanced esophageal cancer: experience 
at a single institution. Arch Surg. 2004;139:532-8.
16. Malthaner RA, Wong RK, Rumble RB, Zuraw L; Members of the Gastrointestinal 
Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based 
Care. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a sys-
tematic review and meta-analysis. BMC Med 2004;2:35.
17. Marin FA, Lamônica-Garcia VC, Henry MA, Burini RC. Grade of esophageal 
cancer and nutritional status impact on postsurgery outcomes. Arq Gastroenterol. 
2010;47:348-53.
18. Morgan MA, Lewis WG, Crosby TD, Escofet X, Roberts SA, Brewster AE, 
Harvard TJ, Clark GW. Prospective cohort comparison of neoadjuvant chemo-
radiotherapy versus chemotherapy in patients with oesophageal cancer. Br J 
Surg. 2007:94:1509-14.
19. Pinotti HW. Subtotal esophagectomy by transmediastinal tunnel without thora-
cotomy. Rev Assoc Med Bras. 1977;23:395-8.
20. Ramos AC, Araujo MR, Lopes LR, Andreollo NA. Role of  the vitamin C in 
diethylnitrosamine-induced esophageal cancer in Wistar rats. Acta Cir Bras. 
2009;24:183-8.
21. Schena M, La Rovere E, Solerio D, Bustreo S, Barone C, Daniele L, Buffoni L, 
Bironzo P, Sapino A, Gasparri G, Ciuffreda L, Ricardi U. Neoadjuvant che-
mo-radiotherapy for locally advanced esophageal cancer: a monocentric study. 
Tumori. 2012;98:451-7.
22. Sugimachi K, Yaita A, Ueo H, Natsuda Y, Inokuchi K. A safer and more reliable 
operative technique for esophageal reconstruction using a gastric tube. Am J 
Surg. 1980;140:471-4.
23. Talsma K, van Hagen P, Grotenhuis BA, Steyerberg EW, Tilanus HW, van 
Lanschot JJ, Wijnhoven BP. Comparison of  the 6th and 7th Editions of  the 
UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol. 
2012;19:2142-8.
24. Tercioti Jr V, Lopes LR, Coelho-Neto JS, Andreollo NA. New aspects of  the 
neo-adjuvant therapy in esophageal squamous cell carcinoma: a review of medical 
literature. ABCD Arq Bras Cir Dig. 2009;22:33-40.
25. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman 
M. Randomized trial of  preoperative chemoradiation versus surgery alone in 
patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-13.
26. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that com-
pared neoadjuvant chemoradiation and surgery to surgery alone for resectable 
esophageal cancer. Am J Surg. 2003;185:538-43.
27. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegou-
wen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonen-
kamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, 
Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen 
MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, 
Tilanus HW, van der Gaast A; CROSS Group. Preoperative chemoradiotherapy 
for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
28. Worni M, Martin J, Gloor B, Pietrobon R, D’Amico TA, Akushevich I, Berry 
MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? 
An analysis using the surveillance epidemiology and end results registry from 
1998 to 2008. J Am Coll Surg. 2012;215:643-51.
29. Zhang X, Watson DI, Jamieson GG, Bessell JR, Devitt PG. Neoadjuvant chemo-
radiotherapy for esophageal carcinoma. Dis Esophagus. 2005;18:104-8.
Received 24/1/2013.
Accepted 19/2/2013.
